The Fly | CAPS

Specialized Peptide Therapeutics Focus: Their core expertise centered on developing peptide-based drugs, allowing for targeted research and development in a specific biological modality.

Proprietary Intellectual Property Portfolio: Ownership of patents and licenses related to their specific peptide compounds and associated technologies, providing a foundation for exclusivity.

Historical Clinical Development Experience: Accumulated experience in advancing multiple drug candidates through various phases of preclinical and clinical trials, building institutional knowledge.

Clinical Trial Outcomes Risk: Failure of product candidates in clinical trials or significant delays in development could prevent or delay market entry.

Regulatory Approval Risk: Inability to obtain or maintain necessary regulatory approvals (e.g., FDA) for product candidates could halt commercialization.

Capital Requirements and Funding Risk: The company may require substantial additional funding to continue operations and product development, which may not be available on favorable terms or at all.

Charts

Specialized Peptide Therapeutics Focus: Their core expertise centered on developing peptide-based drugs, allowing for targeted research and development in a specific biological modality.

Proprietary Intellectual Property Portfolio: Ownership of patents and licenses related to their specific peptide compounds and associated technologies, providing a foundation for exclusivity.

Historical Clinical Development Experience: Accumulated experience in advancing multiple drug candidates through various phases of preclinical and clinical trials, building institutional knowledge.

Clinical Trial Outcomes Risk: Failure of product candidates in clinical trials or significant delays in development could prevent or delay market entry.

Regulatory Approval Risk: Inability to obtain or maintain necessary regulatory approvals (e.g., FDA) for product candidates could halt commercialization.

Capital Requirements and Funding Risk: The company may require substantial additional funding to continue operations and product development, which may not be available on favorable terms or at all.